| Citation: |
WANG Jie, YAN Xuebing, WEI Benfei. Effect observation of postoperative radiotherapy combined with systemic chemotherapy in treating patients with cervical cancer in early stage[J]. Journal of Clinical Medicine in Practice, 2023, 27(11): 11-16. DOI: 10.7619/jcmp.20223685
|
To evaluate the clinical effect of postoperative radiotherapy combined with systemic chemotherapy in treating patients with cervical cancer in early stage.
The clinical materials of 152 patients with postoperative radiotherapy in stage Ⅰb to Ⅱa of cervical cancer were retrospectively analyzed, and they were divided into radiotherapy combined with systemic chemotherapy group and simple radiotherapy group, with 76 cases in each group. The clinical materials and conditions of recurrence and metastasis were compared between the two groups.
In the 152 patients with cervical cancer in early stage, the recurrence rate after postoperative radiotherapy was 20.39%. Univariate and multivariate analyses showed that vascular cancer thrombus, deep interstitial infiltration, parametrial infiltration and pelvic lymph node metastasis were the independent risk factors for postoperative recurrence of cervical cancer after radiotherapy (P < 0.05). In the radiotherapy combined with systemic chemotherapy group, the ratios of patients with adenocarcinoma and other pathological types, larger tumor diameter, vascular cancer thrombus and pelvic lymph node metastasis were significantly higher than those in the simple radiotherapy group (P < 0.05 or P < 0.01). In the 88 elderly (≥50 years old) patients with cervical cancer in early stage, univariate and multivariate analyses showed that parametrial invasion and pelvic lymph node metastasis were the independent risk factors of postoperative recurrence after radiotherapy in elderly patients with cervical cancer (P < 0.05).
Vascular cancer thrombus, deep interstitial infiltration, parametrial infiltration and pelvic lymph node metastasis are the independent risk factors for postoperative recurrence after radiotherapy in patients with cervical cancer in early stage. For early cervical cancer patients with moderate to high risk factors, postoperative radiotherapy combined with systemic chemotherapy can help reduce risk of recurrence. Parametrial infiltration and pelvic lymph node metastasis are the independent risk factors of postoperative recurrence in elderly patients with cervical cancer in early stage.
| [1] |
ARBYN M, WEIDERPASS E, BRUNI L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis[J]. Lancet Glob Health, 2020, 8(2): e191-e203. doi: 10.1016/S2214-109X(19)30482-6
|
| [2] |
刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-14. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLZD202102001.htm
|
| [3] |
中国抗癌协会妇科肿瘤专业委员会. 子宫颈癌诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31(6): 474-489. doi: 10.19401/j.cnki.1007-3639.2021.06.06
|
| [4] |
KOH W J, ABU-RUSTUM N R, BEAN S, et al. Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2019, 17(1): 64-84. doi: 10.6004/jnccn.2019.0001
|
| [5] |
王焜煜, 王元景, 孔为民. 2020年美国放射肿瘤学会宫颈癌放射治疗指南解读[J]. 中国临床医生杂志, 2021, 49(4): 403-407. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLYS202104010.htm
|
| [6] |
SUN H Y, TANG Q, CHEN J H, et al. Cisplatin concurrent chemoradiotherapy vs adjuvant radiation in stage ⅠB/ⅡA cervical cancer with intermediate risk factors, treated with radical surgery: a retrospective study[J]. Onco Targets Ther, 2018, 11: 1149-1155. doi: 10.2147/OTT.S158214
|
| [7] |
KIM H, CHO W K, KIM Y J, et al. Significance of the number of high-risk factors in patients with cervical cancer treated with radical hysterectomy and concurrent chemoradiotherapy[J]. Gynecol Oncol, 2020, 157(2): 423-428. doi: 10.1016/j.ygyno.2020.02.031
|
| [8] |
PETERS W A 3rd, LIU P Y, BARRETT R J 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix[J]. J Clin Oncol, 2000, 18(8): 1606-1613. doi: 10.1200/JCO.2000.18.8.1606
|
| [9] |
NANTHAMONGKOLKUL K, HANPRASERTPONG J. Longer waiting times for early stage cervical cancer patients undergoing radical hysterectomy are associated with diminished long-term overall survival[J]. J Gynecol Oncol, 2015, 26(4): 262-269. doi: 10.3802/jgo.2015.26.4.262
|
| [10] |
GOPU P, ANTONY F, CYRIAC S, et al. Updates on systemic therapy for cervical cancer[J]. Indian J Med Res, 2021, 154(2): 293-302.
|
| [11] |
BRODEUR M N, DEJEAN R, BEAUCHEMIN M C, et al. Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer[J]. Gynecol Oncol, 2021, 162(2): 277-283. doi: 10.1016/j.ygyno.2021.05.023
|
| [12] |
KWON J, EOM K Y, KIM Y S, et al. The prognostic impact of the number of metastatic lymph nodes and a new prognostic scoring system for recurrence in early-stage cervical cancer with high risk factors: a multicenter cohort study (KROG 15-04)[J]. Cancer Res Treat, 2018, 50(3): 964-974. doi: 10.4143/crt.2017.346
|
| [13] |
VAN DER VELDEN J, MOM C H, VAN LONKHUIJZEN L, et al. Analysis of isolated loco-regional recurrence rate in intermediate risk early cervical cancer after a type C2 radical hysterectomy without adjuvant radiotherapy[J]. Int J Gynecol Cancer, 2019: ijgc-2019-000445.
|
| [14] |
COHEN P A, JHINGRAN A, OAKNIN A, et al. Cervical cancer[J]. Lancet, 2019, 393(10167): 169-182. doi: 10.1016/S0140-6736(18)32470-X
|
| [15] |
SAGI-DAIN L, ABOL-FOL S, LAVIE O, et al. Cervical cancer with intermediate risk factors: is there a role for adjuvant radiotherapyA systematic review and a meta-analysis[J]. Gynecol Obstet Invest, 2019, 84(6): 606-615. doi: 10.1159/000501683
|
| [16] |
RYU S Y, KIM M H, NAM B H, et al. Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study[J]. Br J Cancer, 2014, 110(2): 278-285. doi: 10.1038/bjc.2013.716
|
| [17] |
LEE J Y, LEE Y Y, PARK J Y, et al. Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3[J]. J Gynecol Oncol, 2023, 34(2): e51. doi: 10.3802/jgo.2023.34.e51
|
| [18] |
HUANG H, FENG Y L, WAN T, et al. Effectiveness of sequential chemoradiation vs concurrent chemoradiation or radiation alone in adjuvant treatment after hysterectomy for cervical cancer: the STARS phase 3 randomized clinical trial[J]. JAMA Oncol, 2021, 7(3): 361-369. doi: 10.1001/jamaoncol.2020.7168
|
| [19] |
MATSUO K, MABUCHI S, OKAZAWA M, et al. Clinical implication of surgically treated early-stage cervical cancer with multiple high-risk factors[J]. J Gynecol Oncol, 2015, 26(1): 3. doi: 10.3802/jgo.2015.26.1.3
|
| [20] |
MATSUO K, SHIMADA M, AOKI Y, et al. Comparison of adjuvant therapy for node-positive clinical stage ⅠB-ⅡB cervical cancer: systemic chemotherapy versus pelvic irradiation[J]. Int J Cancer, 2017, 141(5): 1042-1051.
|
| [21] |
ZHONG M L, WANG Y N, LIANG M R, et al. Consolidation chemotherapy in early-stage cervical cancer patients with lymph node metastasis after radical hysterectomy[J]. Int J Gynecol Cancer, 2020, 30(5): 602-606.
|
| 1. |
殷华芳，沙莎，蔡依玲，于波，刘佳，何佳，孙玲娣，王坚. 宫颈癌放射治疗相关卵巢损伤的分子机制及防治策略研究进展. 实用临床医药杂志. 2024(10): 141-144 .
 本站查看
| |
| 2. |
张玉洲，李晓敏，孙少霖. 蓝萼乙素通过Akt/BAD通路对宫颈癌裸鼠移植瘤生长的影响. 现代药物与临床. 2024(06): 1384-1389 .
| |
| 3. |
沈静，张丽华，徐晶晶，吕萌萌，吴东辰. 卡瑞利珠单抗联合白蛋白结合型紫杉醇对晚期宫颈癌患者肿瘤标志物、免疫功能和血管新生指标的影响. 现代生物医学进展. 2024(13): 2592-2595 .
| |
| 4. |
曾美男. 早期宫颈癌术后不同治疗方法的临床效果分析. 实用妇科内分泌电子杂志. 2023(24): 28-30+85 .
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: